HH
BRNS

HSG Holding’s Barinthus Biotherapeutics BRNS Stock Holding History

HSG Holding’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Hold
1,420,473
– – 0.07% 16
2025
Q4 		$42.2M Hold
1,420,473
– – 2.23% 7
2025
Q3 		$1.96M Hold
1,420,473
– – 0.1% 16
2025
Q2 		$1.32M Hold
1,420,473
– – 0.07% 17
2025
Q1 		$1.16M Hold
1,420,473
– – 0.07% 15
2024
Q4 		$1.39M Hold
1,420,473
– – 0.06% 16
2024
Q3 		$1.89M Hold
1,420,473
– – 0.07% 16
2024
Q2 		$1.95M Hold
1,420,473
– – 0.07% 15
2024
Q1 		$3.62M Hold
1,420,473
– – 0.34% 13
2023
Q4 		$4.3M Hold
1,420,473
– – 0.5% 14
2023
Q3 		$4.39M Hold
1,420,473
– – 0.47% 16
2023
Q2 		$2.93M Hold
1,420,473
– – 0.33% 15
2023
Q1 		$3.18M Hold
1,420,473
– – 0.33% 14
2022
Q4 		$3.34M Hold
1,420,473
– – 0.34% 14
2022
Q3 		$4.55M Hold
1,420,473
– – 0.49% 15
2022
Q2 		$6.32M Buy
+1,420,473
New +$6.84M 0.58% 13

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

HSG Holding's BRNS Position: Q1 2026 in Review

HSG Holding held its Barinthus Biotherapeutics (BRNS) position steady in Q1 2026 at 1,420,473 shares worth $1.16M. The position accounts for 0.07% of the portfolio, ranked #16.

HSG Holding first reported a position in BRNS in Q2 2022 and has held it in 16 quarters since. The position peaked at $42.2M in Q4 2025. 14 funds tracked by Wall St. Rank hold BRNS as of Q1 2026.

  • HSG Holding held 1,420,473 shares of Barinthus Biotherapeutics worth $1.16M as of Q1 2026.
  • HSG Holding left its Barinthus Biotherapeutics share count unchanged in Q1 2026.
  • Barinthus Biotherapeutics made up 0.07% of HSG Holding's portfolio in Q1 2026, its #16 holding.
  • HSG Holding first reported a position in Barinthus Biotherapeutics in Q2 2022 and has held it in 16 quarters since.
  • HSG Holding's Barinthus Biotherapeutics position peaked at $42.2M in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2026.

Based on HSG Holding's 13F filing for Q1 2026, filed 15 May 2026.